Now Offering PD-L1 Testing

MLabs is now offering PDL-1 testing for Metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.

NOW AVAILABLE: New NGS Myeloid Panel! 

NOW AVAILABLE: NGS Myeloid Panel!  MLabs is excited to announce the addition of our new NGS Myeloid
Panel: For any myeloid or suspected myeloid neoplasm.

COVID-19 IgG Serology Testing Now Available!

Serology testing for SARS-CoV-2 is now available for ordering. A separate process for testing and screening of health care workers and Michigan Medicine affiliates will be communicated in the coming weeks. 

MLABS offers NGS to detect PIK3CA mutation targeted by New Metastatic Breast Cancer Treatment

Many patients living with metastatic breast cancer (mBS) now have a new treatment option.

In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...

MLabs NGS Panels Detects NTRK Fusion Genes in Select Solid Tumor Patients for FDA-approved Vitrakvi® (larotrectinib) Therapy

MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...